Featured Articles

KAND567 is an orally available small molecule that blocks CX3CR1, the Fractalkine receptor. It is to be noted that Fractalkine receptor is an immunomodulating factor termed as …
Read More...

Maker of innovative, needle-free injection technology,  PharmaJet asserted venturing into a global license agreement with  Genexine, for the development and commercialization of DNA…
Read More...

The Janssen Pharmaceutical Companies of Johnson and Johnson asserted extrapolation of data that exemplified 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at…
Read More...

GenePOC asserted the launch of GenePOC GBS LB assay which is implied to be in its home market for the revogene instrument. The revogene is an automated stand-alone instrument that…
Read More...

Anew Era TMS is a provider of transcranial magnetic stimulation TMS for treating individuals with medication-resistant depression and skin disorders. TMS offers and extends a safe and…
Read More...

Non-profit organization, Aeras committed to developing vaccines against TB declared results from breakthrough Clinical Trial aiding evidence that TB Vaccines could forbid sustained…
Read More...

Roche and Flatiron Health asserted that the two partners have ventured into a definitive agreement enumerating that Roche will acquire all shares of Flatiron  Health from an existing…
Read More...

AbbVie asserted results from the double-blinded extension phase of the Phase 2 CELEST Study, exhibiting that many patients treated with upadacitinib who attained clinical response after…
Read More...

Novartis declared additional results from the SCULPTURE study marking that two thirds of moderate to severe plaque psoriasis patients treated with Cosentyx exhibited zero impact of skin…
Read More...

Teva Pharmaceutical Industries asserted the commercial availability of QVAR RediHaler Inhalation Aerosol to patients in both 40 mcg and 80 mcg strengths by prescription in the U.S QVAR…
Read More...

Banyan Biomarkers asserted that the U.S FDA has extended De Novo request for the commercialization of Banyan BTI Brain Trauma Indicator), an in vitro diagnostic blood test to aid in the…
Read More...

Celgene Corporation asserted that data from a randomized, placebo-controlled, multi-center, phase II clinical trial of apremilast in patients with active ulcerative colitis who had…
Read More...

Arterys Inc declared its fifth 510 (k) clearance for Arterys Oncology AI suite and is milestone indicative of the company's momentum in applying AI to further medical imaging accuracy…
Read More...

Tusker Medical announced the enrollment of first- in-office patients in the OTTER Study implied for Tusker's  TULA (Tubes Under Local Anesthesia) System. Via an approved Investigational…
Read More...

Intralytix proclaimed having sought Food and Drug Administration's clearance to commence Phase I/IIa Clinical Trials at Mount Sinai hospital in New York. Dating back to July,2015,…
Read More...

ImmunoQure will collaborate with Servier to advance ImmunoQure's therapeutic human Interferon-α autoantibody through preclinical development and into the clinic where Servier will be…
Read More...

Bristol-Myers Squibb Company and Nektar Therapeutics collaborate commercially for Nektar's lead immuno-oncology program, NKTR-214. The companies will jointly develop and…
Read More...

Novartis division, Sandoz asserted that the US FDA ha sanctioned the roll out and launch of Glatopa (glatiramer acetate injection) 40 mg/mL. Glatopa was developed under a…
Read More...

Roche asserted that it has received FDA clearance for the cobas Factor II and Factor V Test for use on the cobas 4800 system. The test enables laboratories to simultaneously evaluate …
Read More...

Mallinckrodt plc  confirmed the enrollment of first patient for the company's Phase 1 study evaluating the safety and tolerance of ExpressGraft C9T1 skin tissue in the treatment of…
Read More...